Nifty 17401.65 (1.37%)
Sensex 58461.29 (1.35%)
Nifty Bank 36508.25 (0.39%)
Nifty IT 36157.85 (2.06%)
Nifty Financial Services 17982.9 (1.26%)
Adani Ports 739.10 (4.40%)
Asian Paints 3180.60 (1.35%)
Axis Bank 676.10 (-0.52%)
B P C L 378.85 (2.74%)
Bajaj Auto 3328.40 (2.43%)
Bajaj Finance 7180.50 (2.01%)
Bajaj Finserv 17758.15 (2.16%)
Bharti Airtel 732.55 (1.43%)
Britannia Inds. 3578.50 (1.22%)
Cipla 921.25 (-0.74%)
Coal India 159.30 (2.41%)
Divis Lab. 4777.30 (0.53%)
Dr Reddys Labs 4662.75 (1.22%)
Eicher Motors 2451.55 (0.54%)
Grasim Inds 1723.85 (2.63%)
H D F C 2807.80 (3.85%)
HCL Technologies 1184.70 (2.42%)
HDFC Bank 1525.75 (1.40%)
HDFC Life Insur. 705.30 (1.65%)
Hero Motocorp 2472.70 (1.00%)
Hind. Unilever 2383.30 (1.64%)
Hindalco Inds. 432.10 (1.69%)
I O C L 120.65 (2.51%)
ICICI Bank 722.40 (-0.73%)
IndusInd Bank 945.55 (1.27%)
Infosys 1748.25 (1.94%)
ITC 225.45 (1.60%)
JSW Steel 646.75 (1.50%)
Kotak Mah. Bank 1964.25 (0.56%)
Larsen & Toubro 1789.20 (0.18%)
M & M 849.55 (1.78%)
Maruti Suzuki 7324.95 (0.71%)
Nestle India 19503.20 (0.54%)
NTPC 128.70 (0.78%)
O N G C 144.00 (1.23%)
Power Grid Corpn 214.50 (3.52%)
Reliance Industr 2482.85 (0.64%)
SBI Life Insuran 1188.05 (1.99%)
Shree Cement 26289.80 (0.76%)
St Bk of India 477.00 (0.36%)
Sun Pharma.Inds. 766.25 (2.80%)
Tata Consumer 773.25 (0.06%)
Tata Motors 479.10 (0.81%)
Tata Steel 1112.40 (2.76%)
TCS 3642.90 (1.82%)
Tech Mahindra 1629.65 (2.65%)
Titan Company 2386.50 (1.11%)
UltraTech Cem. 7323.20 (0.01%)
UPL 698.20 (1.12%)
Wipro 646.80 (1.89%)
INFY

Lincoln Pharmaceuticals L..

₹347.3
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

As per analysts rating in the last 6 months, the recommendation is to HOLD Lincoln Pharma.

  • Master Rating:
  • Lincoln Pharmaceuticals has an operating revenue of Rs. 439.71 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 20% is great, ROE of 16% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 84 which is a GOOD score indicating consistency in earnings, a RS Rating of 51 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 146 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Lincoln Pharmaceuticals Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Lincoln Pharmaceuticals Ltd Synopsis

NSE-Medical-Diversified

Lincoln Pharmace is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 413.06 Cr. and Equity Capital is Rs. 20.00 Cr. for the Year ended 31/03/2021. Lincoln Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 20/01/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC024288 and registration number is 024288.
  • Market Cap

    INR 695.64 Cr

  • Sales

    INR 435.11 Cr

  • Shares in Float

    1.20 Cr

  • No of Funds

    9 K

  • Yield

    0.43%

  • Book Value

    1.9

  • U/D Vol Ratio

    1.1

  • LTDebt/Equity

    0%

  • Alpha

    0.06

  • Beta

    0.97

Lincoln Pharmaceuticals Ltd Ownership
Lincoln Pharmaceuticals Ltd Management

Lincoln Pharmaceuticals Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 364.9531304.4949262.60411219.54031189.58043
Fixed Assets Annual Cr 91.241991.066790.3928483.2386874.70276
Total Non Current Assets Annual Cr 162.965151.8325152.2666135.76386127.83945
Total Current Assets Annual Cr 275.7244215.3762194.52118190.24422153.91844
Total Assets Annual Cr 438.6894367.2087346.78778326.00808281.7579
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 182.476152.247131.302109.7794.79
ROE Annual % 16.5516.2717.7514.9214.45
ROCE Annual % 22.1221.1822.8620.1320.03
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 21.3319.0118.9515.9214.79

Lincoln Pharmaceuticals Ltd Technicals

EMA & SMA

CURRENT PRICE

347.3 (7.37)

    • Bullish Moving Averages 13
    • Bearish Moving Averages 3

EMA

  • 20 Day

    337.53

  • 50 Day

    347.95

  • 100 Day

    342.16

  • 200 Day

    312.82

Lincoln Pharmaceuticals Ltd Resistance and support

329.8 PIVOT

  • First Resistance

    337.5

  • Second Resistance

    351.55

  • Third Resistance

    359.25

  • First Support

    315.75

  • Second Support

    308.05

  • Third Support

    294

  • RSI

    53.37

  • MFI

    50.31

  • MACD

    -7.29

  • MACD signal line

    -8.75

Lincoln Pharmaceuticals Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 406,621 12,869,555 31.65%
Week 183,064 7,104,714 38.81%
1 Month 138,867 5,422,749 39.05%
6 Month 277,320 10,668,485 38.47%

Lincoln Pharmaceuticals Ltd Price change analysis

4.1

Over 1 month

Low High
309 370.25

18.85

Over 3 month

Low High
309 414.75

51.75

Over 6 months

Low High
282 414.75

112.85

Over Year

Low High
191.4 414.75

Similar Stocks

News

LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Re

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 fo Read More

LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Re

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 fo Read More

LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Re

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 fo Read More

LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Re

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 fo Read More

LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Re

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 fo Read More

Blogs

FAQs